Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT02603146

Public ClinicalTrials.gov record NCT02603146. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine if hydroxychloroquine (HCQ) is safe and effective for the prevention of future onset of rheumatoid arthritis (RA) in individuals who have elevations of an autoantibody, anti-cyclic citrullinated peptide (anti-CCP3). The following recruitment strategies will be employed towards identifying healthy subjects with elevated anti-cyclic citrullinated peptide (anti-CCP3) levels: -Pre-screening: * first degree relatives of patients with rheumatoid arthritis (RA); * subjects at health-fairs; and * identification of subjects with elevated anti-CCP3 levels in the absence of inflammatory arthritis in rheumatology clinics.

Study identification

NCT ID: NCT02603146
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Enrollment: 144 participants

Conditions and interventions

Conditions

Interventions

Hydroxychloroquine Drug
HCQ Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 27, 2016 (Actual)
Primary completion: Nov 1, 2022 (Actual)
Completion: Nov 1, 2022 (Actual)
Last update posted: Jun 12, 2025

2016 – 2022

United States locations

U.S. sites: 14
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham School of Medicine: Division of Clinical Immunology & Rheumatology	Birmingham	Alabama	35294	—
Cedars Sinai Medical Center: Division of Rheumatology	Los Angeles	California	90048	—
UCLA Medical Center: Division of Rheumatology	Los Angeles	California	90095	—
University of California San Francisco, San Francisco General Hospital	San Francisco	California	94110	—
University of Colorado School of Medicine: Division of Rheumatology	Aurora	Colorado	80045	—
Emory Clinic at 1365 Clifton Road: Emory University School of Medicine	Atlanta	Georgia	30322	—
Brigham & Women's Hospital: Department of Medicine, Rheumatology, Immunology	Boston	Massachusetts	02115	—
University of Massachusetts Memorial Medical Center: Rheumatology	Worcester	Massachusetts	01605	—
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology	Ann Arbor	Michigan	48109	—
Mayo Clinic, Division of Rheumatology	Rochester	Minnesota	55905	—
University of Nebraska Medical Center: Division of Rheumatology	Omaha	Nebraska	68198	—
Northwell Health	Great Neck	New York	110211	—
Oklahoma Medical Research Foundation: Arthritis and Clinical Immunology Research Program	Oklahoma City	Oklahoma	73104	—
University of Texas Southwestern Medical Center, Division of Rheumatic Diseases	Dallas	Texas	75390	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02603146, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 12, 2025 · Synced Oct 25, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02603146 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →